Navigating the complexities of analytical validation for advanced therapies

Quality control is critical for ensuring the safety, efficacy, and consistency of medicinal products, particularly for complex therapies like advanced therapy medicinal products (ATMPs). During drug development, the establishment of an analytical target profile (ATP) is essential, as it defines the acceptable range for product quality based on critical quality attributes (CQAs). This guidance helps shape the analytical procedures required to meet regulatory standards and ensures comparability across development stages.

For ATMPs, challenges arise due to their unique biological characteristics, such as variability in starting materials and manufacturing processes, requiring ongoing method optimization. As these products progress from R&D to GMP robust validation of analytical methods is key to ensuring that these therapies meet their established specifications.

As the field of ATMPs evolves, analytical methods used for testing and release must be continuously refined to handle the complexities of these products. While some assays are analogous to those used in more established biological products, others require significant development to address unique characteristics, such as the analysis of viral vectors like adeno-associated viruses (AAVs). The absence of standard reference materials and the limited availability of clinical samples make validation more challenging, yet strategies like interim reference standards and ongoing communication with regulatory bodies help ensure the successful progression of ATMPs through development.

By adhering to guidelines like ICH Q14 and leveraging emerging technologies, developers can effectively navigate these challenges, ensuring that ATMPs meet the necessary standards for safety, efficacy and regulatory compliance.

Click here to read the full article.
This article was originally published in American Pharmaceutical Review.